What the committee decided

On 23 and 24 July 2026, the US Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) met to consider seven peptide bulk drug substances for inclusion on the 503A Bulk Drug Substances List — the list that determines which substances a US compounding pharmacy may use when preparing a prescription medicine.

The agenda was split across two days:

  • 23 July: BPC-157, KPV, TB-500, MOTS-c
  • 24 July: Emideltide (delta sleep-inducing peptide, DSIP), Semax, Epitalon

The committee voted to recommend six of the seven for addition to the list — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — and voted not to recommend Emideltide. The votes were not unanimous: accounts of the meeting record 8–6 with one abstention for BPC-157, KPV and TB-500, and 7–5 with two abstentions for MOTS-c.

What a PCAC recommendation is not

It is worth being precise about what this decision does and does not do, because much of the coverage has blurred the two.

  • It is not binding. PCAC is an advisory panel. Its recommendations are non-binding, and the FDA makes the final decision through notice-and-comment rulemaking.
  • It is not an approval. None of these peptides is an approved drug. There are no validated indications, no standardised dosing, and no established safety-and-efficacy dataset of the kind a marketing authorisation requires.
  • It is not general permission to compound. Inclusion on the 503A list, if finalised, would permit a licensed compounding pharmacy to prepare a substance for an individual patient holding a valid prescription — a narrow, patient-specific route, not a route to retail supply.
  • Coming off Category 2 is procedural. The April 2026 removal of twelve peptides from the FDA's Category 2 interim list reflected the withdrawal of nominations; it is not a finding of safety.

The UK position: no equivalent route

UK readers should read US compounding headlines with care, because the two systems do not map onto each other.

The UK has no analogue of the 503A Bulk Drug Substances List. The MHRA does not maintain a list of named peptides that pharmacies may compound for human use. Medicines placed on the UK market require a marketing authorisation from the MHRA; the supply of an unlicensed medicine is governed by the Human Medicines Regulations 2012, and the underlying prohibition on unlicensed medicinal products sits in the Medicines Act 1968.

None of the seven peptides discussed by PCAC holds a UK marketing authorisation. As research compounds they sit outside the medicines licensing regime only for as long as they are genuinely supplied for research and not for human use. A US compounding recommendation changes none of that.

Why the contrast matters

  • A US compounding pathway is a regulatory-access question — who may prepare a substance, for whom, and under what oversight. It is not an efficacy finding.
  • The evidence grades in our compound profiles are unchanged by it. A compound does not move from Limited to Moderate because an advisory committee voted on its compounding status.
  • The relevant UK question remains whether a compound has a UK marketing authorisation, and for these seven the answer is no.

What to watch

  • FDA rulemaking on the recommended peptides — the notice-and-comment process that would follow a recommendation.
  • PCAC's next meeting, expected before the end of February 2027, for GHK-Cu, Melanotan II, LL-37, Dihexa acetate and PEG-MGF.
  • Any change in the UK position. At the time of writing there is none.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.